Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819866 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
A Phase 3 study of Cerebral Adrenoleukodystrophy (CALD), sponsored by Minoryx Therapeutics, S.L..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 13
- Study locations
NCT05819866 is a Phase 3 study of Cerebral Adrenoleukodystrophy (CALD) that is actively recruiting participants, run by Minoryx Therapeutics, S.L.. The registered enrollment target is 40 participants, below the 72-participant average among 3 other Cerebral Adrenoleukodystrophy (CALD) trials with a reported enrollment target (44% lower). The trial reports 13 study locations across 7 states.
The verdict
NCT05819866, a Phase 3 study of Cerebral Adrenoleukodystrophy (CALD), is actively recruiting participants, sponsored by Minoryx Therapeutics, S.L..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 13
- Study locations
Study Summary
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Leriglitazone
Study Locations (13)
Other
- Hospital Austral - Buenos Aires
- Federal University of Sao Paulo - São Paulo
- ICM La Pitie Salpetriere - Paris
- Klinik und Poliklinik für Neurologie-Leipzig - Leipzig
- Sir Ganga Ram Hospital - New Delhi
- Hospital 12 de Octubre - Madrid
- National Hospital for Neurology and Neurosurgery - London
California
- Stanford University Medical Center - Palo Alto
Florida
- Neuro Medicine Hospital / UF Health - Gainesville
Maryland
- Kennedy Krieger Institute - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- University of Minnesota - Minneota
Utah
- Health University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05819866
The ClinicalTrials.gov registry entry for NCT05819866 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 3 other Cerebral Adrenoleukodystrophy (CALD) trials with a reported enrollment target (44% lower). The listed sponsor is Minoryx Therapeutics, S.L., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cerebral Adrenoleukodystrophy (CALD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05819866 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05819866 about?
NCT05819866 is a clinical study titled "A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy". A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
What is the current status of trial NCT05819866?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2023-07-12. Estimated completion is 2027-05.
What conditions does trial NCT05819866 study?
This clinical trial studies the following conditions: Cerebral Adrenoleukodystrophy (CALD).
What interventions are being tested in trial NCT05819866?
The interventions under investigation include: Placebo (DRUG), Leriglitazone (DRUG).
Who is sponsoring clinical trial NCT05819866?
This trial is sponsored by Minoryx Therapeutics, S.L., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05819866 being conducted?
This trial has 13 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Adrenoleukodystrophy (CALD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
RECRUITING
-
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
ACTIVE NOT RECRUITING
-
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.